← Leaderboards
Norbert F Voelkel
University Of Colorado Denver
$2,946,899
Attributed
$2,946,899
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$8,782,781 · 6
By mechanism
P01$6,281,928 · 2
R01$2,089,728 · 3
R21$411,125 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Kurt R Stenmark$22,132,904
- Rubin M Tuder$19,596,454
- Mark Robert Nicolls$22,256,364
- Brian Barkley Graham$7,997,357
- Robin Shandas$12,521,834
Others in their field
Top investigators on “Pulmonary Hypertension”
- Marlene Rabinovitch · Stanford University$37,720,523
- Steven M Kawut · Columbia University Health Sciences$25,789,592
- Jason X.-J. Yuan · University Of California, San Diego$23,628,934
- Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru$23,127,355
- Mark Thomas Gladwin · Clinical Center$18,849,194
- Steven Herbert Abman · Johns Hopkins University$18,508,025
Research focus
Pulmonary HypertensionTissue /Cell CultureCell ProliferationVascular Endothelial Growth FactorsApoptosisPatient Oriented ResearchHuman SubjectGene ExpressionDisease /Disorder EtiologyLungChronic Obstructive Pulmonary DiseaseRespiratory Disease /Disorder TherapyMass SpectrometryOxidative StressCell Growth RegulationNecrosisMethod DevelopmentNucleosidesPeptidesHuman TissueClinical ResearchInflammationAngiogenesisBiomarker
Grant awards (18)
Bone marrow-derived precursor cells and angioproliferative PH$186,875
R21 · FY2012 · HL · contact PI
Bone marrow-derived precursor cells and angioproliferative PH$224,250
R21 · FY2011 · HL · contact PI
Pathobiology of Severe Pulmonary Hypertension$1,163,188
P01 · FY2005 · HL
Exhaled Air Biomarkers in COPD$317,015
R01 · FY2005 · HL
Misguided angiogenesis, plexiform pulmonary hypertension$232,637
P01 · FY2005 · HL
Pathobiology of Severe Pulmonary Hypertension$1,137,017
P01 · FY2004 · HL
Exhaled Air Biomarkers in COPD$317,015
R01 · FY2004 · HL
Pathobiology of Severe Pulmonary Hypertension$1,102,618
P01 · FY2003 · HL
Exhaled Air Biomarkers in COPD$316,050
R01 · FY2003 · HL
Pathobiology of Severe Pulmonary Hypertension$130,120
P01 · FY2003 · HL
Pathobiology of Severe Pulmonary Hypertension$1,067,046
P01 · FY2002 · HL
Exhaled Air Biomarkers in COPD$372,144
R01 · FY2002 · HL
Misguided angiogenesis, plexiform pulmonary hypertension$213,409
P01 · FY2002 · HL
Pathobiology of Severe Pulmonary Hypertension$1,235,893
P01 · FY2001 · HL
PROSTACYCLIN SYNTHESIS IN PULMONARY HYPERTENSION$271,034
R01 · FY2001 · HL
Misguided angiogenesis, plexiform pulmonary hypertension$0
P01 · FY2001 · HL
PROSTACYCLIN SYNTHESIS IN PULMONARY HYPERTENSION$265,177
R01 · FY2000 · HL
ENDOTHELIAL CELL PROLIFERATION IN PPH$231,293
R01 · FY2000 · HL